What's in PT. JES Kasih Nusantara Sejahterah's pipeline?

PT. JES Kasih Nusantara Sejahterah has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with PT. JES Kasih Nusantara Sejahterah's portfolio?

Top competitors by shared drug class: Greenwich LifeSciences, Inc., NovaRx Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pt-jes-kasih-nusantara-sejahterah.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

PT. JES Kasih Nusantara Sejahterah — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PT. JES Kasih Nusantara Sejahterah pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Dendritic cell immunotherapy	Dendritic cell immunotherapy	phase 3	Dendritic cell vaccine		Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Greenwich LifeSciences, Inc. · 1 shared drug class
NovaRx Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PT. JES Kasih Nusantara Sejahterah:

Cite this brief

Drug Landscape (2026). PT. JES Kasih Nusantara Sejahterah — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pt-jes-kasih-nusantara-sejahterah. Accessed 2026-05-18.